By PPN News Staff
The FDA approved burosumab-twza (Crysvita, Ultragenyx Pharmaceutical/Kyowa Kirin), the first drug indicated for adults and children aged 1 year and older with X-linked hypophosphatemia (XLH), a rare, inherited form of rickets.
About 3,000 children and 12,000 adults in the United States have XLH, a progressive and lifelong skeletal disorder characterized by renal phosphate wasting caused by excess fibroblast growth factor 23 (FGF23) production. In children, XLH causes